Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

Christine I. Chen, C. Tom Kouroukis, Darrell White, Michael Voralia, Edward Stadtmauer, A. Keith Stewart, John J. Wright, Jean Powers, Wendy Walsh, Elizabeth Eisenhauer

Research output: Contribution to journalArticlepeer-review

143 Scopus citations

Abstract

Purpose: To evaluate the efficacy and toxicity of single-agent bortezomib in Waldenström's macroglobulinemia (WM). Patients and Methods: Symptomatic WM patients, untreated or previously treated, received bortezomib 1.3 mg/m 2 intravenously days 1, 4, 8, and 11 on a 21-day cycle until two cycles past complete response (CR), stable disease (SD) attained, progression (PD), or unacceptable toxicity. Responses were based on both paraprotein levels and bidimensional disease measurements. Results: Twenty-seven patients were enrolled. A median of six cycles (range, two to 39) of bortezomib were administered. Twenty-one patients had a decrease in immunoglobulin M (IgM) of at least 25%, with 12 patients (44%) reaching at least 50% IgM reduction. Using both IgM and bidimensional criteria, responses included seven partial responses (PRs; 26%), 19 SDs (70%), and one PD (4%). Total response rate was 26%. IgM reductions were prompt, with nodal responses lagging. Hemoglobin levels increased by at least 10 g/L in 18 patients (66%). Most nonhematologic toxicities were grade 1 to 2, but 20 patients (74%) developed new or worsening peripheral neuropathy (five patients with grade 3, no grade 4), a common cause for dose reduction. Onset of neuropathy was within two to four cycles and reversible in the majority. Hematologic toxicities included grade 3 to 4 thrombocytopenia in eight patients (29.6%) and neutropenia in five (19%). Toxicity led to treatment discontinuation in 12 patients (44%), most commonly because of neuropathy. Conclusion: Bortezomib has efficacy in WM, but neurotoxicity can be dose limiting. The slower response in nodal disease may require prolonged therapy, perhaps with a less intensive dosing schedule to avoid early discontinuation because of toxicity. Future studies of bortezomib in combination with other agents are warranted.

Original languageEnglish (US)
Pages (from-to)1570-1575
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number12
DOIs
StatePublished - Apr 20 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group'. Together they form a unique fingerprint.

Cite this